Actuate Therapeutics, INC 8-K filings

Actuate Therapeutics received a notice from Nasdaq regarding its Market Value of Listed Securities (MVLS) falling below the required $50 million threshold, with 180 days to regain compliance.

Actuate Therapeutics stockholders elected two Class II directors and ratified the appointment of Crowe LLP as auditor.

Actuate Therapeutics received FDA clearance for a Phase 1/2 study of its oral elraglusib tablet, aiming to improve patient outcomes in multiple solid tumor indications.

Actuate Therapeutics adds Dr. Martin Huber, an experienced oncology drug developer, to its Board of Directors to bolster its leadership in advancing novel cancer therapies.

Actuate Therapeutics announced positive follow-up data from its Phase 2 trial of elraglusib, showing extended overall survival benefit in metastatic pancreatic cancer patients.

Actuate Therapeutics, Inc. has entered into an At-the-Market sales agreement to potentially raise up to $100 million through the sale of common stock.

Actuate Therapeutics, Inc. has outlined its official channels for disseminating material information to investors and the public, including its website, press releases, SEC filings, and social media.

Actuate Therapeutics, a clinical-stage biopharmaceutical company, announced the pricing of an underwritten public offering to raise $15.0 million in gross proceeds.

Actuate Therapeutics, Inc. has entered into a private placement agreement to issue common stock and warrants, raising approximately $4.7 million in gross proceeds to support its working capital and general corporate purposes, while acknowledging a 'going concern' risk.

Actuate Therapeutics, Inc. announced positive topline Phase 2 data for its drug elraglusib in combination with gemcitabine/nab-paclitaxel for first-line metastatic pancreatic cancer, demonstrating a significant overall survival benefit and high tolerability.

Actuate Therapeutics announced compelling topline Phase 2 results for elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) for first-line metastatic pancreatic cancer, demonstrating a statistically significant improvement in median overall survival and a doubling of the one-year survival rate.

Actuate Therapeutics, Inc. announced that its stockholders elected three Class I directors and ratified Crowe LLP as its independent registered public accounting firm for the 2025 fiscal year at the Annual Meeting held on May 22, 2025.

Actuate Therapeutics reports statistically significant improvement in overall survival in a Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel (GnP) for first-line treatment of metastatic pancreatic cancer.

Actuate Therapeutics enters into a \$50 million common stock purchase agreement with B. Riley Principal Capital II, providing the company with flexible access to capital.

Actuate Therapeutics sets the date for its first annual stockholders meeting and outlines deadlines for stockholder proposals and director nominations.

Actuate Therapeutics reports statistically significant improvements in survival rates and overall survival in a Phase 2 trial of elraglusib combined with chemotherapy for metastatic pancreatic cancer.

Actuate Therapeutics has been granted Rare Pediatric Disease Designation by the FDA for elraglusib, a novel GSK-3 inhibitor, for the treatment of Ewing sarcoma, a rare and aggressive childhood cancer.

Actuate Therapeutics has changed its independent auditor from KMJ Corbin & Company LLP to Crowe LLP, effective August 19, 2024.

Actuate Therapeutics successfully closed its IPO, raised $19.2 million in net proceeds, and appointed new independent directors while amending its corporate charter and bylaws.